<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><description>米内网是中国领先的集医药健康产业研究、医院市场研究、零售市场研究、商业渠道研究、互联网在线医药健康信息服务于一体的综合性专业信息服务平台。目前拥有七项数据分析技术获国家专利，每月收集数据3000多万条，有63个专业数据库为医药健康行业服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 01 Apr 2021 17:24:15 +0800</pubDate><image><url>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</url><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>20款吸入剂厉害了！8个1类新药、20个首仿来袭，正大天晴亮了，成都倍特发力</title><link>https://mp.weixin.qq.com/s/1aGF8aFjIavollO_lu3GcQ</link><description></description><content:encoded><![CDATA[20款吸入剂厉害了！8个1类新药、20个首仿来袭，正大天晴亮了，成都倍特发力]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>【喜讯】符合第五批集采品种注射用更昔洛韦，普利制药再下一城获意大利批准</title><link>https://mp.weixin.qq.com/s/3r7ppeypOEePa3U5q56aiQ</link><description></description><content:encoded><![CDATA[【喜讯】符合第五批集采品种注射用更昔洛韦，普利制药再下一城获意大利批准]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>【瞩目】这家药企开挂了，两款创新药接连获批</title><link>https://mp.weixin.qq.com/s/MKv-yG1OpAnaKcVXrAu2Fw</link><description></description><content:encoded><![CDATA[【瞩目】这家药企开挂了，两款创新药接连获批]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>【关注】助力疼痛康复，藏医药蓄势待发</title><link>https://mp.weixin.qq.com/s/TobKddSlq-Q28m17x0yS0A</link><description></description><content:encoded><![CDATA[【关注】助力疼痛康复，藏医药蓄势待发]]></content:encoded><pubDate>Thu, 01 Apr 2021 16:06:30 +0800</pubDate></item><item><title>中成药TOP20出炉！扬子江、步长……17个独家产品霸屏，天士力、康缘1类新药来袭</title><link>https://mp.weixin.qq.com/s/mP_IoURi0iWVujrMX5UoKw</link><description></description><content:encoded><![CDATA[中成药TOP20出炉！扬子江、步长……17个独家产品霸屏，天士力、康缘1类新药来袭]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>【市场】8亿注射剂苑东首家过评，12个品种已过评</title><link>https://mp.weixin.qq.com/s/rbnbiVUQE8fv6ifeafT-vg</link><description></description><content:encoded><![CDATA[【市场】8亿注射剂苑东首家过评，12个品种已过评]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>【瞩目】科伦将拿下$6亿重磅乙肝药</title><link>https://mp.weixin.qq.com/s/R26DLbip00ONMAzpWqeG_Q</link><description></description><content:encoded><![CDATA[【瞩目】科伦将拿下$6亿重磅乙肝药]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>【重磅】信立泰发威！8款创新药围攻心脑血管市场</title><link>https://mp.weixin.qq.com/s/6BygA9HR1qWAd6GtwzIGeg</link><description></description><content:encoded><![CDATA[【重磅】信立泰发威！8款创新药围攻心脑血管市场]]></content:encoded><pubDate>Wed, 31 Mar 2021 16:30:40 +0800</pubDate></item><item><title>龙头易主，创新药“神助攻”恒瑞封王！国产贴膏剂逼退原研，齐鲁新药来了</title><link>https://mp.weixin.qq.com/s/75e_aMvxWDIxE2N_4JplSg</link><description></description><content:encoded><![CDATA[龙头易主，创新药“神助攻”恒瑞封王！国产贴膏剂逼退原研，齐鲁新药来了]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item><item><title>【重磅】成都倍特新药将获批！搅局200亿抗病毒药物市场</title><link>https://mp.weixin.qq.com/s/2ZNT3Zv9CHk6Q6Abjgqfew</link><description></description><content:encoded><![CDATA[【重磅】成都倍特新药将获批！搅局200亿抗病毒药物市场]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item><item><title>【瞩目】35亿抗哮喘药，这家广州药企将强势入局</title><link>https://mp.weixin.qq.com/s/wcKWcxZOqmwcARweMHfnjQ</link><description></description><content:encoded><![CDATA[【瞩目】35亿抗哮喘药，这家广州药企将强势入局]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item><item><title>【火爆】好医生、科伦领军20亿中药大品种，京新要出新招？</title><link>https://mp.weixin.qq.com/s/QjovntB66_6i4qho1_yAfw</link><description></description><content:encoded><![CDATA[【火爆】好医生、科伦领军20亿中药大品种，京新要出新招？]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:48:44 +0800</pubDate></item><item><title>扬子江领军化药品牌TOP10！正大天晴、石药……国产新药崛起，罗氏“三驾马车”受冲击</title><link>https://mp.weixin.qq.com/s/D32mGlZ8Vmla_26ktt1oMQ</link><description></description><content:encoded><![CDATA[扬子江领军化药品牌TOP10！正大天晴、石药……国产新药崛起，罗氏“三驾马车”受冲击]]></content:encoded><pubDate>Mon, 29 Mar 2021 16:17:33 +0800</pubDate></item><item><title>【瞩目】海思科大爆发！抗ED药首仿获批，重磅注射剂将开展Ⅲ期临床</title><link>https://mp.weixin.qq.com/s/CCVluKsxh0f6ymV2w35gmQ</link><description></description><content:encoded><![CDATA[【瞩目】海思科大爆发！抗ED药首仿获批，重磅注射剂将开展Ⅲ期临床]]></content:encoded><pubDate>Mon, 29 Mar 2021 16:17:33 +0800</pubDate></item><item><title>【关注】20亿注射剂大品种！石四药第二家过评</title><link>https://mp.weixin.qq.com/s/omJ6OKxhxbqkJ1i15cbelQ</link><description></description><content:encoded><![CDATA[【关注】20亿注射剂大品种！石四药第二家过评]]></content:encoded><pubDate>Mon, 29 Mar 2021 16:17:33 +0800</pubDate></item><item><title>【获批】辉瑞迎劲敌！科伦拿下$8亿抗肿瘤药</title><link>https://mp.weixin.qq.com/s/QgV-3LI9AGPZndM5Xcy5Ww</link><description></description><content:encoded><![CDATA[【获批】辉瑞迎劲敌！科伦拿下$8亿抗肿瘤药]]></content:encoded><pubDate>Mon, 29 Mar 2021 16:17:33 +0800</pubDate></item><item><title>奥赛康、东阳光药、齐鲁……43个新药获批临床！200亿市场巨变在即，武田新药来袭</title><link>https://mp.weixin.qq.com/s/7JYXx9rtbgAqp6T1gLH8UQ</link><description></description><content:encoded><![CDATA[奥赛康、东阳光药、齐鲁……43个新药获批临床！200亿市场巨变在即，武田新药来袭]]></content:encoded><pubDate>Sun, 28 Mar 2021 07:55:19 +0800</pubDate></item><item><title>多款国产1类新药最新销售额曝光！3家“吸金”创新药企亮了，第五批集采最新消息流出</title><link>https://mp.weixin.qq.com/s/etxbQ90QH4HBKptU-2reqw</link><description></description><content:encoded><![CDATA[多款国产1类新药最新销售额曝光！3家“吸金”创新药企亮了，第五批集采最新消息流出]]></content:encoded><pubDate>Sat, 27 Mar 2021 07:57:54 +0800</pubDate></item><item><title>丽珠10亿品种超亮眼，独家注射剂再涨600%！研发投入激增，生物药丰收在望</title><link>https://mp.weixin.qq.com/s/EMwiDsqvkYERHSSSWMSQdA</link><description></description><content:encoded><![CDATA[丽珠10亿品种超亮眼，独家注射剂再涨600%！研发投入激增，生物药丰收在望]]></content:encoded><pubDate>Fri, 26 Mar 2021 16:22:01 +0800</pubDate></item><item><title>【重磅】40亿抗肿瘤注射剂，领军企业恒瑞过评，齐鲁再下一城</title><link>https://mp.weixin.qq.com/s/njGIMRJdYbosQsg1LgKIMg</link><description></description><content:encoded><![CDATA[【重磅】40亿抗肿瘤注射剂，领军企业恒瑞过评，齐鲁再下一城]]></content:encoded><pubDate>Fri, 26 Mar 2021 16:22:01 +0800</pubDate></item></channel></rss>